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Loss-of-function mutations in progranulin (GRN) cause ubiquitin- and TAR DNA-binding protein 43 (TDP-43)-
positive frontotemporal dementia (FTLD-U), a progressive neurodegenerative disease affecting 10% of
early-onset dementia patients. Here we expand the role of GRN in FTLD-U and demonstrate that a common
genetic variant (rs5848), located in the 30-untranslated region (UTR) of GRN in a binding-site for miR-659,
is a major susceptibility factor for FTLD-U. In a series of pathologically conﬁrmed FTLD-U patients without
GRN mutations, we show that carriers homozygous for the T-allele of rs5848 have a 3.2-fold increased risk
to develop FTLD-U compared with homozygous C-allele carriers (95% CI: 1.50–6.73). We further demonstrate
that miR-659 can regulate GRN expression in vitro, with miR-659 binding more efﬁciently to the high risk T-
allele of rs5848 resulting in augmented translational inhibition of GRN. A signiﬁcant reduction in GRN protein
was observed in homozygous T-allele carriers in vivo, through biochemical and immunohistochemical
methods, mimicking the effect of heterozygous loss-of-function GRN mutations. In support of these ﬁndings,
the neuropathology of homozygous rs5848 T-allele carriers frequently resembled the pathological FTLD-U
subtype of GRN mutation carriers. We suggest that the expression of GRN is regulated by miRNAs and
that common genetic variability in a miRNA binding-site can signiﬁcantly increase the risk for FTLD-U.
Translational regulation by miRNAs may represent a common mechanism underlying complex neurodegen-
erative disorders.
INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a progressive
neurodegenerative disorder representing 5% of all dementia
patients (1). It is the second most common form of early-onset
neurodegenerative dementia after Alzheimer’s disease (AD),
affecting 10–20% of patients with an onset of dementia before
65 years. FTLD patients present with prominent behavioral and
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which evolve gradually into cognitive impairment and dementia
(2,3). FTLD may occur alone or in combination with motor
neuron disease (MND) (4). The most common neuropathology
associated with clinical FTLD is frontal and anterior temporal
lobe atrophy with neuronal inclusions immunoreactive for ubi-
quitinandTAR DNA-binding protein43 (TDP-43),butnegative
for tau and a-synuclein (FTLD-U) (5–7). Neuronal cytoplasmic
inclusions(NCIs)intheneocortex,striatumandthedentatefascia
of the hippocampus are the pathological hallmarks of FTLD-
U. Up to four subtypes of FTLD-U have been delineated that
are based on the distribution of NCIs, dystrophic neurites and
the presence of neuronal intranuclear inclusions (NIIs) (8–10).
Interestingly, all cases with GRN mutations have a common
FTLD-U subtype, characterized by NCIs, short, thin neurites in
layer II of the cortex and lentiform NIIs (11–13). This subtype
is referred to as Type 1 by Mackenzie et al.( 8 )a n dT y p e3b y
Sampathu et al.( 1 0 ) .
FTLD has a high familial incidence with up to 50% of
patients reported to have a family history of dementia. Recent
molecular genetic advances in the ﬁeld of FTLD have revealed
that the genetic basis of FTLD-U is heterogeneous, and the
causative mechanisms are just starting to be unraveled (14).
Loss-of-function mutations in the gene encoding the secreted
growth factor progranulin (GRN)o nc h r o m o s o m e1 7h a v e
been identiﬁed as a major cause of familial FTLD-U and are
present in up to 25% of familial FTLD-U patients worldwide
(15–17). In addition, mutations in the valosin containing
protein gene (VCP) and the gene encoding the charged
multivesicular body protein (CHMP2B) have been reported in
a small number of FTLD-U families (18,19). Despite these
recent developments, it is evident that additional FTLD-U
genes and genetic risk factors remain to be identiﬁed to
explain the disease in the majority of the familial patients and
in apparently sporadic FTLD-U patients.
We previously reported the identiﬁcation of 23 different
pathogenic loss-of-function mutations in GRN in 10% of the
patients in our Mayo Clinic FTLD series, including a small
number of apparently sporadic patients (17). In the present
study, we expand the spectrum of mutational mechanisms that
can lead to the loss of functional GRN. Using cell-based
systems and in vivo studies we demonstrate that a common
genetic variant (rs5848), located in the 30-untranslated region
(UTR) of GRN in a binding-site for micro-RNA (miRNA)
miR-659 signiﬁcantly increases the risk of developing
FTLD-U most likely through suppressed translation of GRN.
Our ﬁndings suggest that translational regulation by miRNAs
may present a common mechanism underlying complex neuro-
degenerative disorders.
RESULTS
Association study of rs5848 with FTLD-U
We previously performed sequencing analyses of GRN in an
extended population of FTLD patients (n ¼ 378) derived from
the Mayo Clinic FTLD series to assess the genetic contribution
of GRN mutations to FTLD (17). A close inspection of our
sequencing results in the subgroup of non-GRN mutation
carriers (n ¼ 339) revealed a statistically signiﬁcant deviation
from the expected Hardy–Weinberg equilibrium (HWE) for
the common polymorphism rs5848 (P ¼ 0.002), which was
attributable to an excess of homozygous patients (Table 1).
Deviations from HWE were not observed for any of the other
genetic variants in GRN. We re-genotyped rs5848 using a pre-
designed Taqman genotyping assay and conﬁrmed all rs5848
genotypes in the FTLD patient series. Subsequent analyses of
rs5848 in a large cohort of control individuals ascertained at
Mayo Clinic Jacksonville (MCJ) and Mayo Clinic Scottsdale
(MCS) showed a selective increase in the TT genotype
frequency in FTLD patients (16%) compared with control
individuals (9%) (Pgenotypic ¼ 0.002) (Table 2).
To further conﬁrm the genetic contribution of rs5848 to the
development of FTLD, we focused our analyses on a homo-
geneous series of patients with a primary neuropathological
diagnosis of FTLD-U with conﬁrmed TDP-43-positive neur-
onal inclusions, derived from the MCJ brain bank and an
age- and gender-matched control group ascertained at MCJ
and MCS. Of the 81 genealogically unrelated FTLD-U
patients identiﬁed in our brain bank, 19 (23.5% of the
FTLD-U population) carried a pathogenic loss-of-function
GRN mutation and were excluded from the study. One VCP
and one LRRK2 mutation carrier were also excluded, resulting
in a total of 59 FTLD-U patients for the genetic studies. Using
logistic regression analyses of rs5848, we showed a highly
signiﬁcant association of rs5848 with FTLD-U (Padjusted ¼
0.003), resulting from an increase in the TT genotype
frequency of rs5848 in FTLD-U patients (25.4%) compared
with control individuals (9.9%) (Table 3). We calculated that
within our series, the odds ratio (OR) to develop FTLD-U for
carriers homozygous for the minor T-allele of rs5848 compared
with homozygous C-allele carriers was 3.18 [Padjusted ¼ 0.003;
95% conﬁdence interval (CI): 1.50–6.73]. In contrast, individ-
uals heterozygous for rs5848 did not show an increased risk to
develop FTLD-U (Padjusted ¼ 0.74; OR ¼ 1.12; 95% CI: 0.59–
2.10) (Table 3). Since MND pathology is rare or absent in GRN
loss-of-function mutation carriers, we also re-analyzed the
association excluding patients with MND pathology (n ¼ 11),
Table 1. Hardy–Weinberg calculation of rs5848 in Mayo Clinic FTLD
patients
Non-PGRN FTLD patients (n ¼ 339)
rs5848 genotypes Observed Expected Overall P-value
nn
CC 160 145.4 0.002
CT 124 153.2
TT 55 40.4
Table 2. Genotype frequencies of rs5848 in Mayo Clinic FTLD case–control
series
rs5848 genotypes Controls
(n ¼ 934)
Patients
(n ¼ 339)
Overall P-value
n % n %
CC 463 49.6 160 47.2 0.002
CT 384 41.1 124 36.6
TT 87 9.3 55 16.2
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carriers to 3.76 (95% CI: 1.69–8.39; Padjusted ¼ 0.001). Com-
parison of gender, age at death and brain weight of FTLD-U
patients by rs5848 genotype groups did not show signiﬁcant
differences (mean age at death was 71.6+7.4 years in CC,
76.0+10.5 years in CT and 75.5+11.3 years in TT carriers).
Detailed genetic analyses in GRN genomic region
To study whether rs5848 is the likely functional variant
underlying the association with FTLD-U or whether another
genetic variant in linkage disequilibrium (LD) with rs5848
could be responsible for the observed association, we deter-
mined the LD structure underlying the GRN genomic region
and performed single SNP and haplotype association analyses
(Supplementary Material, Results). A panel of 12 additional
SNPs was selected for single SNP and haplotype association
analyses in the FTLD-U patient-control series: seven tagging
SNPs identiﬁed in the genomic sequencing analyses that
together with rs5848 capture 94% of the genetic diversity
in the GRN region (Supplementary Material, Fig. S1; Fig. 1,
SNPs in blue) and ﬁve SNPs in considerable LD with
rs5848 selected from the downstream haplotype block (Sup-
plementary Material, Fig. S2: Fig. 1, SNPs in green). Single
SNP association analyses did not reveal SNPs that were
more strongly associated with FTLD-U than rs5848 (Sup-
plementary Material, Table S1). Moreover, haplotype analyses
in the GRN genomic region and in a downstream haplotype
block containing rs5848 only showed signiﬁcant association
when the risk T-allele of rs5848 was included (Supplementary
Material, Table S2). Sequencing and genotyping analyses
further revealed multiple GRN genetic backgrounds for the
risk T-allele of rs5848, further favoring rs5848 as the potential
functional variant underlying the observed association
(Supplementary Material, Results and Table S3).
rs5848 is located in a predicted miRNA binding site of GRN
The rs5848 single base change (c. 78C.T) is located 78
nucleotides downstream of the translation termination codon
in the 30-UTR of the GRN transcript in a predicted binding
site for the human speciﬁc miRNA miR-659 (Supplementary
Material, Table S4). miRNAs are small non-coding RNAs that
bind via imperfect base-pairing with target mRNAs to posttran-
scriptionally modulate their expression (20). We hypothesized
that rs5848 may increase the risk for FTLD-U by altering the
miRNA regulation of GRN, similar to previous studies in
which a single nucleotide change in a miRNA target site had
been shown sufﬁcient to affect miRNA regulation (21,22).
By means of in silico analyses using the RNA folding and
two-state hybridization servers (http://frontend.bioinfo.rpi.
edu/applications/mfold/) we predicted that miR-659 binds to
the GRN 30-UTR through a perfect complementarity of the
‘seed’ region at position 2–7 of the miRNA and an additional
30match of an adenosine anchor at position 1 (23). However,
depending on the presence of the C-allele or the T-allele at
rs5848, the positioning of miR-659 with respect to the
miRNA binding site in GRN was expected to shift, resulting
in the formation of three additional base-pairs at the 50end
of the miRNA when the risk T-allele of rs5848 was present
(Fig. 2). The stronger binding of miR-659 to the GRN
mRNA containing the T-allele was expected to result in a
more efﬁcient inhibition of GRN translation leading to
reduced GRN expression levels.
rs5848 affects GRN protein levels but not mRNA
levels in FTLD-U patients
To determine the effect of rs5848 on GRN expression, we
performed GRN immunoblot analyses using brain extracts
derived from cerebellum of FTLD-U patients homozygous
for the C- or T-allele. Using western blot analyses we
observed a signiﬁcant decrease in GRN protein levels in TT
carriers compared with CC carriers (P , 0.001) (Fig. 3A
and B). These data were further supported by immunohisto-
chemical analysis, which showed a signiﬁcant reduction in
GRN burden in the granular cell layer of the cerebellum in
TT compared with CC patients (P , 0.001) (Supplementary
Material, Fig. S3). To further quantify the reduction in
GRN, we re-extracted brain homogenates from the cerebellum
of FTLD-U rs5848 CC, CT and TT carriers and determined
GRN expression using an enzyme-linked immunoassay
(ELISA). A signiﬁcant 30% decrease in GRN levels was
observed in rs5848 TT carriers compared with CC carriers
in the TBS-X fraction (P , 0.001) (Fig. 3C). Intermediate
levels of GRN protein were observed in FTLD-U patients
heterozygous for rs5848 supporting a dose-dependent decrease
of GRN with each T-allele (data not shown).
As expected from a translational repression by miR-659,
real-time mRNA expression analyses did not show a signiﬁ-
cant difference in GRN mRNA levels between rs5848 CC
and TT carriers (Fig. 3D).
miR-659 inhibits GRN translation at rs5848
To provide evidence that miR-659 binds to GRN and can regu-
late the expression of GRN levels in vitro, we transiently
transfected human M17 cells with 12 nM of miR-659 to
mimic the expression of endogenous miR-659, or 12 nM
negative control miRNAs, miR-C1 and miR-C2 (Ambion).
Forty-eight hours post-transfection, cells were harvested and
the endogenous human GRN levels produced by the M17
cells were measured by immunoblot analyses. A highly
signiﬁcant decrease in the expression of endogenous GRN
was observed in M17 cells treated with miR-659 (P , 0.001)
(Fig. 4A and B).
To further study the regulation of GRN expression by
miR-659, we inserted the full-length 304 bp GRN 30-UTR
sequence containing the wild-type C-allele at position 78
Table 3. Logistic regression analyses of rs5848 in FTLD-U patient–control
series
rs5848
genotypes
Controls
(n ¼ 433)
Patients
(n ¼ 59)
Padjusted-value OR 95% CI
n % n %
CC 199 46.0 21 35.6 — — —
CT 191 44.1 23 39.0 0.74 1.12 0.59–2.10
TT 43 9.9 15 25.4 0.003 3.18 1.50–6.73
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REPORT miRNA expression reporter vector system and
transiently transfected the construct into mouse N2A neuro-
blastoma cells (Fig. 4C). Co-transfection of a high dose
(12 nM) of miR-659 or negative control miR-C2 in these
cells resulted in signiﬁcantly reduced expression of luciferase
(representing GRN protein) in the presence of miR-659 further
conﬁrming the functional potential of the mRNA–miRNA
duplex (Fig. 4D). We next constructed a luciferase construct
with the GRN 30-UTR sequence in which the complete 18 bp
predicted binding site of miR-659 was deleted (position
71–88 downstream of the termination codon; vectorD18)
(Fig. 4C). Addition of 12 nM miR-659 to N2A cells trans-
fected with vectorD18 failed to repress the luciferase activity
(Fig. 4D), supporting the hypothesis that miR-659 binds to
the predicted binding-site in the 30-UTR of GRN, overlapping
with rs5848 at position 78.
To further study the differential regulation of GRN
expression resulting from the presence of the wild-type ‘C’
or risk ‘T’ allele at rs5848, we created a luciferase construct
containing the GRN 30-UTR including the T-allele at position
78 (Fig. 4C). Co-transfection of the luciferase construct con-
taining either the C-allele or the T-allele with variable low
doses (0.01–100 pM) of miR-659 or negative control
miR-C2 showed a dose-dependent reduction of luciferase
activity derived from constructs containing the T-allele, reach-
ing statistical signiﬁcance at doses of 5 and 100 pM (P ,
0.02) (Fig. 4E). A strong translational repression of the
T-allele construct was also observed at 20 pM, however this
result was non-signiﬁcant (P ¼ 0.06). Translational repression
of luciferase activity from the wild-type rs5848-C construct
was not observed for cells treated with miR-659 at any of
these low doses (0.01–100 pM) (Fig. 4F).
miR-659 is expressed in human brain
To conﬁrm the expression of miR-659 in human cells and in
brain, we used a Taqman expression assay speciﬁc for
miR-659 (Applied Biosystems). Positive expression of mature
miR-659 was observed in both M17 cells and cerebellum
(Supplementary Material, Fig. S4). Additional analyses using
RNA extracted from seven different brain regions of a control
brain (amygdala, occipital lobe, temporal lobe, frontal lobe,
hippocampus, caudate and cerebellum) showed miR-659 expres-
sion in all analyzed regions, including frontal and temporal
neocortex, which is most affected in FTLD-U (data not shown).
Correlation of rs5848 genotypes with FTLD-U
pathological subtype
To determine whether the neuropathology of rs5848 TT
carriers resembles the pathology of GRN loss-of-function
mutation carriers, we determined the FTLD-U pathological
subtype as proposed by the classiﬁcation scheme of
Mackenzie et al. (8) for all FTLD-U cases included in the
genetic analyses of rs5848 with parafﬁn-embedded tissue
blocks available for additional studies (n ¼ 57). In addition,
we determined the absence or presence of lentiform NIIs.
Figure 1. Overview of genetic variants included in the GRN association studies. Each of the 13 genetic variants included in the association studies are shown
relative to their position on chromosome 17q21.31. SNP rs5848 located in the 30-UTR of GRN and strongly associated with FTLD-U is shown in red, while all
other SNPs included in the GRN genomic region are in blue. SNPs from the downstream haplotype block are in green.
Figure 2. In silico analyses of the pairing of miR-659 to the predicted binding
site in the 30-UTR of GRN.( A) Base-pairing in the presence of wild-type
C-allele at rs5848 or (B) risk T-allele at rs5848. The presence of the risk
T-allele is expected to lead to the formation of three additional base-pairs at
the 50end of miR-659 compared with the wild-type C-allele, resulting in a
stronger binding and more efﬁcient inhibition of GRN translation.
3634 Human Molecular Genetics, 2008, Vol. 17, No. 23Overall, FTLD-U subtypes could be determined for 54
FTLD-U patients resulting in 23 patients with FTLD-U type
1 (42.6%), 15 patients with FTLD-U type 2 (27.8%) and 16
patients with FTLD-U type 3 (29.6%). For the remaining
three patients, the FTLD-U subtype could not be unambigu-
ously assigned in part because inclusions were sparse
(FTLD-U type 1 versus type 3). Stratiﬁcation of FTLD-U
patients by rs5848 genotype showed a non-signiﬁcant increase
in the frequency of FTLD-U type 1 pathology (resembling
GRN mutation carriers) in TT carriers (66.7% in TT versus
33.3% in CT and CC carriers; P ¼ 0.26; Fisher exact test)
(Fig. 5A). Moreover, NIIs were signiﬁcantly more common
in the subgroup of TT carriers compared with CT or CC car-
riers (66.7% in TT versus 23.8% in CT and 27.8% in CC car-
riers; P ¼ 0.02; Fisher exact test) (Fig. 5B). Finally, MND
pathology, which is rare or absent in GRN mutation carriers,
was only present in one of the 15 FTLD-U patients hom-
ozygous for the risk T-allele (6.7%) compared with ﬁve out
of 23 CT carriers (21.7%) and ﬁve out of 21 CC carriers
(23.8%).
DISCUSSION
We previously showed that heterozygous loss-of-function
mutations in GRN are an important cause of FTLD, explaining
up to 25% of familial patients with the FTLD-U pathological
subtype. In this study we focused our attention on the role of
the common genetic variant rs5848, located in the 30-UTR of
GRN. This was stimulated by our observation of a deviation
from the expected HWE for rs5848 in an extensive Mayo
Clinic FTLD patient series, due to a selective increase in
the TT genotype frequency in patients compared with
control individuals. We hypothesized that if rs5848 is a true
genetic risk factor for FTLD, the genetic association would
be strongest in a homogeneous population of patients with
FTLD-U pathology. To test this hypothesis, we performed
genetic association analyses in a pathology-conﬁrmed
FTLD-U series derived from the MCJ brain bank and con-
ﬁrmed the genetic risk associated with rs5848. In our series,
the OR to develop FTLD-U for carriers homozygous for the
minor T-allele of rs5848 compared with homozygous
Figure 3. Correlation of rs5848 genotypes with GRN expression levels in vivo.( A) Representative immunoblot analyses of six cerebellar tissue samples of
FTLD-U patients with the indicated genotypes, showing reduced expression of GRN in rs5848 TT compared with CC carriers. A loss-of-function GRN mutation
carrier (Mut) is included for comparison. (B) Quantiﬁcation of immunoblotted GRN in cerebellar tissue samples of FTLD-U rs5848 TT or CC carriers (n ¼ 7i n
each group). GRN expression was normalized to GAPDH. Data represent mean+SEM. (  indicates P , 0.001; two sample t-test). (C) Quantiﬁcation of GRN
protein levels by ELISA in the TBS-X fraction of cerebellar tissue samples of FTLD-U rs5848 TT and CC carriers (n ¼ 7 in each group). GRN expression was
30% lower in FTLD-U rs5848 TT compared with CC carriers. Four loss-of-function GRN mutation carriers are included for comparison. (  indicates P ,
0.001; two sample t-test). (D) Relative GRN mRNA expression determined by quantitative RT-PCR in cerebellar brain samples of FTLD-U rs5848 TT or
CC carriers (n ¼ 7 in each group). No signiﬁcant difference in mRNA expression levels was observed. Data represent mean+SEM.
Human Molecular Genetics, 2008, Vol. 17, No. 23 3635C-allele carriers was 3.18 (95% CI: 1.50–6.73; Padjusted ¼
0.003). Detailed genetic analyses of GRN and its ﬂanking
genomic regions further showed multiple haplotype back-
grounds for the risk T-allele of rs5848 and did not reveal
other genetic variants or haplotypes that were more strongly
associated with FTLD-U, favoring rs5848 as the functional
variant underlying the association.
We determined that rs5848 is located in the 30-UTR of
GRN within a predicted binding site for the human speciﬁc
miRNA miR-659. miRNAs are a widely distributed class of
non-coding RNAs that play an integral role in gene regulation
by binding to partially complementary sites in the 30-UTR
of target mRNA transcripts, thereby inducing translational
repression (20). Using in silico analyses we predicted a
stronger binding (reducing GRN expression) of miR-659 to
the GRN 30-UTR containing the risk T-allele compared with
the wild-type C-allele of rs5848.
To support the hypothesis that rs5848 is indeed a functional
variant regulating GRN expression, we determined GRN
expression levels in brain extracts derived from FTLD-U
rs5848 CC and TT carriers by western blot analyses, ELISA
and immunohistochemistry. These in vivo analyses conﬁrmed
Figure 4. Functional analyses of the GRN regulation by miR-659 in vitro.( A) Representative immunoblot analyses of human M17 cells transfected with
miR-659 or control miRNAs (miR-C1 and miR-C2). (B) Quantiﬁcation of immunoblotted GRN in human M17 cells transfected with miR-659 or control
miRNAs. GRN expression was normalized to GAPDH. Data are from four independent experiments and represent mean+SEM. (  indicates P , 0.001;
two sample t-test). (C) Schematic overview of the pMIR-REPORT vector containing a CMV promoter, ﬁreﬂy luciferase gene, full-length 30-UTR of GRN
and SV40 poly A-tail. Constructs with wild-type C-allele and risk T-allele of rs5848 at position 78 in 30-UTR were created as well as a D18 construct in
which the complete predicted binding site of miR-659 was deleted (position 71–88 in the 30-UTR). (D) Luciferase expression in N2A cells transfected with
pMIR-REPORT-rs5848C or pMIR-REPORT- D18 and co-transfected with high dose (12 nM) miR-659 or miR-C2. Relative luciferase activity was determined
as ﬁreﬂy luciferase activity normalized to Renilla luciferase activity. Each experiment was repeated six times. miR-659 signiﬁcantly decreased the expression of
ﬁreﬂy luciferase using the wild-type pMIR-REPORT-rs5848C vector, but not using the pMIR-REPORT-D18 in which the miR-659 binding site was deleted.
Data represent mean+SEM. (  indicates P , 0.001; two sample t-test). (E–F) pMIR-REPORT-rs5848C and pMIR-REPORT-rs5848T vectors were transfected
in N2A cells and co-transfected with variable low doses (0.01–100 pM) of miR-659 or miR-C2. Each experiment was repeated three times. A signiﬁcant
reduction in the expression of ﬁreﬂy luciferase was observed in the presence of 5 and 100 pM of miR-659 from the rs5848T construct (D,   P , 0.02; two-tailed
t-test), while no reduction in the expression of ﬁreﬂy luciferase from the rs5848C construct was observed at any of the doses. Data represent mean+SEM.
3636 Human Molecular Genetics, 2008, Vol. 17, No. 23the functional capacity of rs5848. Compared with CC carriers, a
statistically signiﬁcant 30% decrease in GRN protein levels
was observed in FTLD-U rs5848 TT carriers. Furthermore,
intermediate levels of GRN protein were observed in
FTLD-U patients heterozygous for rs5848 supporting a dose-
dependent decrease of GRN protein levels with each T-allele.
As expected from a translational suppression of GRN by
miRNAs, GRN mRNA expression levels were not signiﬁcantly
different between FTLD-U rs5848 CC and TT carriers.
Using cell-based systems we further demonstrated that
miR-659 binds to the predicted binding site in the 30-UTR
of GRN and is able to suppress GRN expression in vitro.T o
determine the differential regulation of GRN expression
resulting from the wild-type C-allele or risk T-allele of
rs5848, we generated luciferase reporter constructs expressing
ﬁreﬂy luciferase under the regulation of the GRN 30-UTR car-
rying both rs5848 alleles. Our data suggested that miR-659
binds more efﬁciently to the risk T-allele than the wild-type
C-allele, as demonstrated by the dose-dependent translational
inhibition of the luciferase reporter (representing GRN
protein) from the T-allele construct at low miRNA doses
ranging from 5 to 100 pM (Fig. 4E). No translational repres-
sion was observed using the wild-type C-allele constructs,
further supporting the differential effect of rs5848 (Fig. 4F).
Together with the conﬁrmation of positive expression of
miR-659 in human brain, these results strongly support the
functional potential of the miR-659/GRN mRNA complex.
Of note, neither the binding site of miR-659 in the 30-UTR
of GRN, nor the gene encoding miR-659 on human chromo-
some 22q13, are conserved in other vertebrate or invertebrate
species, prohibiting the modeling of the regulation of GRN by
miR-659 in non-human systems.
If rs5848 increases FTLD-U risk by miRNA-mediated
translational repression of GRN, one would expect a signiﬁcant
proportion of homozygous T-allele carriers to develop a patho-
logical FTLD-U phenotype resembling GRN loss-of-function
mutation carriers. Indeed, histological subtyping of FTLD-U
patients from our cohort, blinded to their rs5848 genotype
status, revealed that .65% of patients homozygous for the
risk T-allele (10/15 patients) had FTLD-U consistent with
Mackenzie type 1 (12). In addition, compared with the other
rs5848 genotype groups, the frequency of lentiform NIIs was
signiﬁcantly higher in homozygous T-allele carriers (P ¼
0.02). Finally, MND pathology, which is rare or absent in
GRN loss-of-function mutation carriers, was only present in
one of the 15 FTLD-U patients homozygous for the risk
T-allele (6.6%). Re-analyses of the genetic association study
excluding patients with a pathological diagnosis of FTD-
MND increased the OR for homozygous T-allele carriers
to 3.76 (95% CI: 1.69–8.39; Padjusted ¼ 0.001). The strong
similarity in pathological presentation between GRN loss-of-
function mutation carriers and patients homozygous for the
rs5848 T-allele provides additional support for the hypothesis
that rs5848 increases FTLD-U risk by reducing the expression
of GRN.
In 2 years, 57 different pathogenic GRN loss-of-function
mutations have been reported in 160 genealogically unrelated
FTLD families (Alzheimer Disease and Frontotemporal
Dementia Mutation Database, http://www.molgen.ua.ac.be/
FTDmutations/). The majority of these mutations are non-
sense, frameshift and splice-site mutations that introduce a
premature stop codon leading to the degradation of mutant
RNA by the process of nonsense-mediated decay and the sub-
sequent loss of 50% functional GRN (15). The identiﬁcation
in this study of homozygosity of the T-allele of rs5848 as a
major risk factor for FTLD-U, represents yet another way in
which genetic variation in GRN may lead to FTLD-U via a
decrease in the levels of functional GRN. In this case, haploin-
sufﬁciency is predicted to result from increased suppression of
GRN translation through altered miRNA regulation. Our ﬁnd-
ings suggest a scenario whereby a decrease in GRN expression
below a critical threshold results in the development of
FTLD-U. While a single GRN null allele can sufﬁciently
reduce GRN expression levels to cause FTLD-U, two copies
of the risk T-allele of rs5848 are required (but may not be suf-
ﬁcient) to reduce the GRN expression below this critical
threshold. We propose that a homozygous state of the risk
T-allele at rs5848 combined with other environmental and/or
genetic factors, will ultimately determine which individuals
develop FTLD-U. In this respect, the association of rs5848
with FTLD-U is similar to many other neurodegenerative dis-
eases where genetic variability at the same loci implicated in
Mendelian pathogenic forms of the disease predispose to spora-
dic forms of the disease (24–29). Whether rs5848 may also
contribute to the development of other TDP43-proteinopathies
(such as amyotrophic lateral sclerosis) or may determine the
presence of TDP-43 pathology in more common neurodegen-
erative conditions such as AD (30) needs further investigation.
The assumption of a role for miRNA pathways in neurode-
generation is intriguing and has been previously suggested
based on experiments in mice, ﬂies and cultured neurons in
which the enzyme Dicer (required for miRNA maturation)
was genetically inactivated (31–33). A role for speciﬁc
miRNAs in the development of common neurodegenerative
diseases has further been suggested by comparing changes
in miRNA expression proﬁles in brain samples derived
from patients and controls (32,34). Based on the
possible role of miRNA dysregulation of GRN in FTLD pre-
sented in this study and the knowledge that overexpression
Figure 5. Pathological characterization of 54 FTLD-U patients stratiﬁed by
rs5848 genotype. (A) Stratiﬁed by rs5848 genotype, the percentage of patients
with each FTLD-U pathological subtype is shown. FTLD-U patients homozy-
gous for the risk T-allele show the highest frequency of FTLD-U type 1. (B)
Stratiﬁed by rs5848 genotype, the percentage of patients with characteristic
lentiform NIIs is shown. FTLD-U patients homozygous for the risk T-allele
present signiﬁcantly more frequent with NIIs compared with heterozygous
CT and homozygous CC carriers (P ¼ 0.02, Fisher exact test).
Human Molecular Genetics, 2008, Vol. 17, No. 23 3637of neurodegenerative disease proteins, such as the amyloid
precursor protein in AD (35) and a-synuclein in Parkinson’s
disease (36), is sufﬁcient to cause disease, we speculate that
regulatory mutations affecting the interaction between
miRNAs and their targets may present a common mechanism
underlying complex neurodegenerative disorders.
MATERIALS AND METHODS
FTLD patient and control populations
Mayo Clinic FTLD case–control series. The Mayo Clinic
FTLD patient series in which the initial observation of a
deviation from HWE for rs5848 was observed has been
previously described in detail (17). A total of 934 control indi-
viduals (mean age at inclusion 64.8+10.9 years) ascertained
through MCJ and MCS were employed to determine initial
rs5848 control genotype frequencies.
FTLD-U case–control series. The MCJ brain bank comprises
.2500 neurodegenerative brain samples primarily ascertained
through The State of Florida Alzheimer’s Disease Initiative
funded through the Department of Elder Affairs, The Einstein
Aging Study (P01-AG03949), The Udall Center for Excellence
in Parkinson’s Disease Research (P50-NS40256), CurePSP/The
Society for Progressive Supranuclear Palsy, Mayo Clinic
ADRC (P50-AG16574), the Alzheimer’s Disease Patient Regis-
try(ADPR)(P30-AG19610)andtheFloridaADRC(P50-25711).
We selected all 81 patients from the MCJ brain bank with the
neuropathological diagnosis of FTLD-U and positive TDP-43
immunostaining. Of these, 19 patients with a GRN loss-of-
function mutation, one VCP mutation carrier and one LRRK2
mutation carrier were excluded from the study, resulting in a
total of 59 FTLD-U patients for genetic and functional analyses.
In this series, the mean age at death was 74.4+9.8 years (range
56–97 years). A selection of 433 control individuals matched
for age and gender to the FTLD-U patient population were
drawn from two large cohorts of unrelated control individuals
collected at MCJ and MCS. The average age at inclusion of
the study was 74.5+5.7 years (range 65–87 years).
Genotyping analyses
Genotyping of all additional SNPs selected for association and
LD structure analyses, with the exception of rs34424835, were
genotyped using pre-designed and custom TaqMan SNP gen-
otyping assays (Applied Biosystems) and analyzed on an ABI
7900HT Fast Real Time PCR system using the SDSv2.2.2
software (for assay information see Supplementary Material,
Table S5). A pre-designed TaqMan SNP genotyping assay
was also used to conﬁrm the rs5848 genotyping observed by
sequencing the Mayo Clinic FTLD patient series and to deter-
mine the genotype frequencies of rs5848 in the FTLD-U and
control individuals.
To genotype the rs34424835 deletion polymorphism,
marker D17S1860 and the newly developed marker
GRN_GT15, each marker was PCR ampliﬁed with one
ﬂuorescently labeled primer, and analyzed on an automated
ABI3100 DNA-analyzer (for primers see Supplementary
Material, Table S6). Alleles were scored using the
GENOTYPER software (Applied Biosystems).
Single SNP and haplotype association analyses
In the FTLD-U patient–control series, single SNP age- and
gender adjusted logistic regression analyses were performed
using the StatsDirect statistical software program (http://
www.statsdirect.com). A genotypic model was used to deter-
mine the risk associated with carrying one or two rare
alleles, using homozygote carriers of the frequent allele as a
reference. Haplotype association was analyzed using the
score method of Schaid et al. (37) with adjustments made
for age and gender. Only haplotypes with an estimated
overall frequency of  5% were considered in the analyses.
The level of signiﬁcance was deﬁned as P , 0.05.
Estimation of haplotype frequencies in GRN genomic
region
The expectation maximization algorithm provided by the
Arlequin package was applied in order to estimate GRN
haplotype frequencies in 35 FTLD patients homozygous for
the rs5848 T-allele.
Immunoblot analyses
Fourteen cerebellar brain samples of FTLD-U cases (seven CC
and seven TT carriers) were selected for immunoblot analyses.
The quality of each of these brain samples was previously
assessed by determining the RNA Integrity Number (RIN)
using an Agilent 2100 Bioanalyzer, and only samples with
RIN values .6 were included in this study. Brain samples
were sonicated in PARIS cell disruption buffer (Ambion/
Applied Biosystems, Austin, TX) supplemented with protease
and phosphatase inhibitors, centrifuged and the protein
concentrations determined with a BCA protein assay (Pierce,
Rockford, IL). Forty micrograms of protein were resolved
by SDS–PAGE using pre-cast 8% Tris–Glycine gels
(Invitrogen, Carlsbad, CA). Separated proteins were transferred
to PVDF membranes and blocked for 1 h at RT with 5% skim
milk/TBST. After incubation with anti-human PCDGF (1:1000;
Zymed, South San Francisco, CA) primary antibody under
blocking conditions, proteins were detected with anti-rabbit
HRP conjugated secondary antibody (1:5000; Southern
Biotech, Birmingham, AL) and ECL-Plus (Perkin Elmer,
Waltham, MA). Quantiﬁcation of immunoreactive bands was
performed by densitometry (Image J, Research Services
Branch, NIMH, Bethesda, MD). GRN protein levels were nor-
malized to GAPDH by re-probing blots with anti-GAPDH
(1:50 000; Biodesign International, Saco, ME) and anti-mouse
HRP conjugated secondary (1:25 000: Southern Biotech) anti-
body. To compare GRN protein levels assessed on separate
immunoblots, a further normalization was performed using a
reference sample included on each blot. In addition, all
immunoblots were run in parallel on the same day, to minimize
variability in experimental conditions.
To determine GRN expression in human M17 cells
transiently transfected with miR-659 or negative control
miRNAs (Cye-3 dye labeled miRNA Negative Control #1
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Ambion), M17 cells were plated on TC-treated Costarw
6-well cell culture plates (Corning, Inc., Corning, NY) at
3.0 10
5 cells per well in antibiotic-free Opti-mem reduced
serum medium supplemented with 10% fetal bovine serum
(Invitrogen). Four hours after plating, cells were transfected
with Lipofectamine 2000 (Invitrogen) using manufacturer’s
instructions, with miR-659, miR-C1 or miR-C2, all at 12 nM.
Three replicates were performed for each treatment.
Forty-eight hours after transfection cells were harvested,
lysed in a detergent-free buffer containing protease and phos-
phatase inhibitors, sonicated and centrifuged. SDS–PAGE and
immunoblot analyses were performed as described above
using 6 mg of protein. Immunoblot analysis was performed
four times for each treatment group. Statistical analyses
were performed using two-tailed t-tests.
GRN ELISA assay
To further quantify GRN expression in human brain, cerebellar
brain samples of 25 FTLD-U cases (7 FTLD-U cases with each
of the rs5848 genotypes and 4 loss-of-function GRN mutation
carriers) were homogenized in 1  TBS (Boston Bioproducts
Inc., Worcester, MA) supplemented with protease and phospha-
tase inhibitors and centrifuged for 5 min at 16 000g at 48C. The
supernatant was saved as the TBS fraction and the pellet was
resuspended and sonicated in TBS-X (1  TBS with 0.1%
Triton X-100). After centrifugation (5 min at 16 000g at 48C),
the supernatant was saved as the TBS-X fraction. The protein
concentration of each fraction was determined using a BCA
protein assay (Pierce). For each sample, 100 mg of protein of
each fraction was analyzed in duplicate using a GRN ELISA
assay (Human Progranulin ELISA Kit, AdipoGen Inc., Seoul,
Korea). Recombinant human GRN provided with the ELISA
kit was used as a standard.
Immunohistochemical analyses
FTLD-U subtyping. Glass-mounted sections (5 mm thick)
of formalin-ﬁxed, parafﬁn-embedded tissue from multiple
brain regions (frontal cortex, temporal cortex, hippocampus,
amygdala, basal ganglia and medulla) were immunostained
for TDP-43 (rabbit polyclonal antibody; 1:3000; ProteinTech
Group, Inc., Chicago, IL) with a DAKO-Autostainer (DAKO-
Cytomaton, Carpinteria, CA) and 3,30-diaminobenzidine as the
chromogen. Sections were lightly counterstained with hema-
toxylin. The distribution of NCIs, dystrophic neurites and
NIIs were noted in each section, and an FTLD-U subtype
was assigned according to a scheme proposed by Mackenzie
et al. (8). Presence or absence of NIIs and MND was also
recorded. Type 1 cases had pleomorphic NCIs and short,
thin neurites in upper cortical layers, as well as pleomorphic
NCIs in the hippocampal dentate fascia, amygdala and
striatum. There was variable ﬁne neuritic pathology in the
hippocampal pyramidal layer. Hypoglossal neurons were not
affected in sections of the medulla, but NCIs were sometimes
found in the inferior olive. Most type 1 cases had lentiform
NIIs. Type 2 cases had long thick dystrophic neurites in the
cortex that did not show a clear laminar distribution, with
sparse cortical NCIs. In contrast to paucity of NCIs in the
cortex, round NCIs were prominent in the dentate fascia and
striatum, but not in lower levels of the neuraxis. Motor
neuron pathology was absent. Type 3 cases had pleomorphic
NCIs in the cortex, including neurons with granular cyto-
plasmic TDP-43 immunoreactive that did not form a discrete
inclusion (‘pre-inclusions’). The amygdala was often affected,
but basal ganglia pathology was minimal. Neurons in the
hypoglossal nucleus often had TDP-43 immunoreactivity.
The frequency of pathological FTLD-U subtypes and
number of FTLD-U patients with NIIs in each of the rs5848
genotype groups were compared using Fisher exact tests.
GRN immunohistochemistry and image analysis. Transverse
sections of the cerebellum, including cortex, white matter
and dentate nucleus were sampled in 10 FTLD-U cases
(5 homozygous C-allele carriers and 5 homozygous T-allele
carriers) previously included in the immunoblot analyses. To
maintain staining consistency, parafﬁn-embedded sections
(5 mm thick) were immunostained with a DAKO-Autostainer
using a primary antibody to human GRN (anti-human progra-
nulin, 1:600, R&D Systems, Inc., Minneapolis, MN) and 3,
30-diaminobenzidine as the chromogen. Sections were lightly
counterstained with hematoxylin. To obtain a quantitative
measure of GRN immunoreactivity by image analysis, immu-
nostained slides were converted into high-resolution digital
images using an Aperio slide scanner (Aperio Technologies,
Vista, CA). Blinded to genotypic information, GRN immunor-
eactivity was quantiﬁed in the granular cell layer of the cer-
ebellum, using a positive pixel count algorithm (Imagescope
version 8; Aperio Technologies, Vista, CA) and expressed as
a percentage of the total area (GRN burden). Statistical com-
parisons were performed using a two-tailed t-test.
Real-time GRN mRNA expression analyses
Total RNA was isolated from cerebellum using the Trizol
Plus RNA Puriﬁcation System (Invitrogen), and its quality
assessed on an Agilent 2100 Bioanalyzer. Only RNA
samples with RNA integrity (RIN) values .6 were included
in the analyses. RNA samples from 14 FTLD-U patients
(7 CC and 7 TT carriers; same samples as included in the
immunoblot analyses) were normalized to 500 ng/ml and
using 3 mg as template, a reverse transcription reaction was
performed using a 2:1 mix of random hexamers and
oligo(dT) primers and the SuperScript III system (Invitrogen).
For expression analyses Applied Biosystems assays were used
for GRN (Hs00173570_m1), and for the endogenous controls
GAPDH (Hs00266705_g1), YWHAZ (Hs00852925_sH) and
HPRT1 (Hs99999909_m1). Real-time PCR was performed
on an ABI 7900 using the TaqManw method. Reactions
contained 1 ml cDNA ampliﬁed with 0.25ml primer/probe
mix and 2.5 ml TaqMan 2X Universal PCR Master Mix. The
cycling parameters as recommended by the manufacturer
were followed; 508C for 2 min, 958C for 10 min, followed
by 40 cycles of 958C for 15 s/ 608C for 1 min. All samples
were run in triplicate and normalized to the geometric mean
of the three endogenous controls as described previously
(38). The FAM-ﬂuorescent signal was analyzed using
SDSv2.2.2 software, and relative quantities of GRN mRNA
were determined using the DDct method.
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The 30-UTR of GRN was ampliﬁed from genomic DNA from
individuals homozygous for the C-allele or T-allele of rs5848
using the following primers: 30-UTR-SpeI-F: AATTACTAG
TGGGACAGTACTGAAGACTCTGC and 30-UTR-HindIII-R:
AATTAAGCTTAGTGTACAAACTTTATTGAAACGC. The
50 end of each primer was designed to include restriction
enzyme digest sites for subsequent digestion and ligation into
the multiple cloning site of the pMIR-REPORT Luciferase
vector (Ambion) to create pMIR-REPORT-rs5848C and
pMIR-REPORT-rs5848T vectors. PCR reactions were per-
formed in 100 ml using 50 ng genomic template and 20 pmol
of each primer. Initial denaturation at 958C was followed by
35 cycles of 948C for 30 s, 60–508C touchdown annealing
for 30 s and 728C for 30 s with a ﬁnal extension at 728Cf o r
10 min. PCR products were puriﬁed using the Qiaquick
puriﬁcation system (Qiagen) both before and after digestion
with SpeIa n dHindIII (New England Biolabs, Ipswich, MA).
To create the pMIR-REPORT-D18 luciferase vector in which
the 18 bp predicted binding site of miR-659 was deleted, we
performed site-directed mutagenesis using the QuikChange
protocol (Stratagene, La Jolla, CA) on a full length GRN
cDNA clone (Invitrogen) using the following primers D18-F:
CAGGCCTCCCTAATTCTCCCTGGAC and D18-R: GTCCA
GGGAGAATTAGGGAGGCCTG. The mutated construct was
subsequently used as template for PCR ampliﬁcation using
the 30-UTR-SpeI-F and 30-UTR-HindIII-R primers, digestion
and ligation into the pMIR-REPORT Luciferase vector as
described earlier. Inserts of all constructs were veriﬁed by
direct sequencing.
Luciferase assays
N2A neuroblastoma cells were plated on TC-treated Costarw
6-well cell culture plates (Corning) at 1.0   10
5 cells per well
in antibiotic-free Opti-mem reduced serum medium sup-
plemented with 10% fetal bovine serum and 2 mML -Glutamine
(Invitrogen). 4 h after plating, cells were transfected with
Lipofectamine 2000 (Invitrogen) using the manufacturer’s pro-
tocol. For the ﬁrst experiment, each well was co-transfected
with 100 ng of either pMIR-REPORT-rs5848C or 100 ng
pMIR-REPORT-D18 and 100 ng of pRL-CMV-renilla lucifer-
ase (Promega, Madison, WI), and treated with either miR-659
or negative control miR-C2 (Ambion) at 12 nM. Six replicates
were performed for each treatment. Twenty-four hours after
transfection, cells were lysed using 250 ml of Reporter Gene
Assay lysis buffer (Roche, Indianapolis, IN) and Luciferase
Fireﬂy (LAF) and Luciferase Renilla (LAR) activities were
measured in triplicate using the dual-luciferase reporter assay
(Promega) on a Veritas microplate luminometer using manu-
facturer’s instructions. To determine the differential regulation
of the rs5848 C- or T-allele constructs by miR-659, luciferase
experiments were further performed by co-transfection of
pMIR-REPORT-rs5848C or pMIR-REPORT-rs5848T with
100 ng of pRL-CMV-renilla luciferase and treatment with
increasing but low doses of miR-659 and negative control
miR-C2 (0.01–100 pM). Three replicates were performed for
each treatment. For each well the relative luciferase activity
(RLA) was calculated as RLA¼LAF/LAR using the average
from three independent measurements. Next, for each quantity
of miRNA, the mean RLA was calculated based on all
replicates. Statistical analyses using t-tests were performed
for each quantity of miRNA by comparing the mean RLA in
cells treated with miR-659 with the mean RLA in cells
treated with negative control miR-C2.
Real-time miR-659 expression analyses
Tissue from the cerebellum of a control brain (pathologically
normal) was dissected and processed using the mirVana
PARIS system (Ambion) to extract RNA enriched for small
RNA species. RNA from an M17 cell pellet was prepared
similarly. A TaqMan microRNA reverse transcription reac-
tion was performed following the manufacturer’s protocol
and using the primers speciﬁc for miR-659 (RT 1514) and
for human control RNU48 (RT1006) (Applied Biosystems).
Real-time PCR was performed on the reverse transcription
products to conﬁrm the presence of miR-659 in the M17
cells and the control brain; each 5 ml reaction contained
0.33 ml reverse transcription product with 0.25 ml primer/
probe mix and 2.5 ml TaqMan 2X Universal PCR Master
Mix (Applied Biosystems) and was cycled as recommended
by the protocol: 958C for 10 min, followed by 40 cycles of
958C for 15 s/608C for 1 min. Samples were run in triplicate
and analyzed using SDSv2.2.2 software. This procedure was
repeated on enriched RNA extracted from amygdala, occipi-
tal lobe, temporal lobe, frontal lobe, hippocampus, caudate
and cerebellum tissue from the same control brain to
conﬁrm the presence of miR-659 in these various brain
regions.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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